PROTACs
-
Rely on Dianthus to overcome roadblocks in your PROTAC characterizations
-
[New] Dianthus with Spectral Shift
Learn how
Overcome your biggest challenges when characterizing PROTAC binary and ternary complexes. -
9 Targeted Protein Degradation conferences you don’t want to miss in 2022
With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on recent progress and the latest approaches. You’ll not...
-
10 terms to help you more easily understand targeted protein degradation
Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...
-
For protein degraders to tackle neurodegenerative diseases, these are the barriers they need to overcome
Neurodegenerative diseases (ND) and cancer are the two major targets in the pipelines of companies focused on targeted protein degradation as a therapeutic modality. Proteins involved in NDs —...
-
Why so many companies are betting on PROTACs as a superior therapeutic modality
With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...
-
Characterizing interactions involving PROTACs or other TACs?
Find out how
NanoTemper tools can help -
MST and TRIC technology to reliably study PROTAC binary and ternary binding in drug development
-
Targeted protein degradation promises to lead the way to effective drugs for challenging targets
-
35:47
Improve your protein degrader design with new ways to discover E3 ligase ligands
Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
-
Ddi1 is a ubiquitin-dependent protease
-
Have a question?
Contact Specialist -
Protein degraders show promising results in drug development pipelines. See progress candidates have made.
There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...
-
Are you building an effective protein degrader?
-
Are you building an effective protein degrader? 4 questions to ask yourself to find out
Protein degraders are getting a lot of attention for being a new and promising modality to treat diseases such as cancer or Alzheimer’s disease. Rather than inhibiting the function of a protein,...
-
Optimize the structure of your next round of PROTAC compounds by analyzing ternary binding affinities using Monolith
-
6 protein degradation conferences in 2021 you can’t afford to miss
Update: See what 2022 conferences you should watch for Conferences in 2021 will gather scientists and experts eager to discuss new discoveries in the emerging field of targeted protein degradation...
-
59:35
How to improve the function of your PROTAC degrader by understanding ternary complex formation
Bifunctional degrader molecules (aka PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases, forming a ternary complex that enables ubiquitination and degradation of the target
-
17:10
Tackle the high-hanging fruits in challenging drug discovery pipelines
There are a number of interesting drug targets that have a reputation of being especially difficult to study in biochemical or biophysical assays. Join us to learn how Dianthus can help you address t
-
Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus
-
Sweet and blind spots in E3 ligase ligand space revealed by a thermophoresis-based assay
-
What are PROTACs: the game-changing modality that promises to tackle undruggable proteins
Almost all pharmaceutical drugs today act by binding to disease-causing proteins and inhibiting their activity. Unfortunately, there are still many target proteins — as much as 85% of the human...
-
Targeting the SARS-CoV‑2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders
-
Loading more...